Anavex doesn't need to impress Wall Street. Anavex needs to impress the FDA. Once that is accomplished we will see what chops Missling has in dealing with Wall Street. And, Wall Street will sit up and take notice when Anavex gets an approved NDA.
The only way Anavex will gain credibility is with continuing progress in its clinical trials, not with some MBA suit who has no idea how to bring a very bold, creative, and complex scientific enterprise across the FDA finish line.
Market Data 
Markets 
AI
